Inhibikase Therapeutics I... (IKT)
undefined
undefined%
At close: undefined
3.32
-0.60%
After-hours Jan 03, 2025, 04:00 PM EST

Company Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain.

The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.

It is also involved in developing various research programs for other neurological diseases.

The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University.

Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc. logo
Country United States
IPO Date Dec 23, 2020
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Dr. Milton H. Werner Ph.D.

Contact Details

Address:
3350 Riverwood Parkway SE
Atlanta, Georgia
United States
Website https://www.inhibikase.com

Stock Details

Ticker Symbol IKT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001750149
CUSIP Number 45719W106
ISIN Number US45719W2052
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. Chief Executive Officer of Clintrex Research Corporation & Member of Scientific Advisory Board
Dr. Milton H. Werner Ph.D. Chief Executive Officer, President & Director
Garth Lees-Rolfe CPA Chief Financial Officer
Dan Williams Controller
Dr. Surendra Singh Head of Chemistry, Manufacturing & Controls

Latest SEC Filings

Date Type Title
Dec 05, 2024 8-K Current Report
Dec 05, 2024 424B3 Filing
Dec 03, 2024 S-3/A [Amend] Filing
Nov 18, 2024 S-3 Filing
Nov 18, 2024 DEF 14A Filing
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 14, 2024 10-Q Quarterly Report
Nov 08, 2024 PRE 14A Filing
Oct 28, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Oct 28, 2024 SC 13G Statement of acquisition of beneficial ownership b...